ALN-APP was designed to treat early-onset Alzheimer’s disease (EOAD) by attaching siRNAs to a lipophilic C16 fatty acid chain, which significantly enhanced the distribution of the siRNA in the brains of rats and monkeys after intrathecal injection. Here, APP is linked to early-onset autosomal dominant Alzheimer disease.